2021
Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR
Sánchez-Zuno GA, Bucala R, Hernández-Bello J, Román-Fernández IV, García-Chagollán M, Nicoletti F, Matuz-Flores MG, García-Arellano S, Esparza-Michel JA, Cerpa-Cruz S, Pérez-Guerrero EE, Muñoz-Valle JF. Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR. Journal Of Clinical Medicine 2021, 11: 120. PMID: 35011861, PMCID: PMC8745239, DOI: 10.3390/jcm11010120.Peer-Reviewed Original ResearchMacrophage migration inhibitory factorHigh disease activityDisease activityDAS28-ESRControl subjectsClinical activityRA clinical activityRheumatoid arthritis patientsExpression of CD74Expression of CXCR4Migration inhibitory factorScavenger-type receptorsDifferent clinical activitiesRA patientsMIF receptorArthritis pathogenesisArthritis patientsCXCR7 expressionInflammatory conditionsReceptor expressionPatientsB cellsDecoy receptorInhibitory factorSoluble CD74
1998
Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF)
BUCALA R. Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF). Annals Of The New York Academy Of Sciences 1998, 840: 74-82. PMID: 9629239, DOI: 10.1111/j.1749-6632.1998.tb09551.x.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMigration inhibitory factorImmune responseRole of MIFInhibitory factorT cell cytokine productionAnti-inflammatory propertiesAnterior pituitary cellsT-lymphocyte factorSteroid therapyLymph nodesCytokine productionImmunosuppressive effectsInflammatory conditionsGlucocorticoid actionT cellsFirst cytokineInflammatory sitesTherapeutic strategiesProinflammatory stimuliPituitary cellsImmune systemLymphocyte factorsGlucocorticoidsInhibitory effect